Long-term results of the iBP elbow prosthesis: beware of destructive metallosis!
- 128 Downloads
The aim of this study was to review the long-term results of the instrumented Bone Preserving (iBP) elbow prosthesis.
Thirty-one patients (10 M, 21F, 28-77 year) were retrospectively evaluated using the Oxford Elbow Score (OES), Disabilities of Arm, Shoulder and Hand Outcome Measure (DASH), Mayo Elbow Performance (MEPS), physical examination and standard radiographs. Kaplan-Meier survival analysis was used.
Thirty-seven primary iBPs have been placed in 31 patients between 2000 and 2007. Six patients (8 prostheses) had died, 10 elbows had been revised and three patients (4 prostheses) were lost to follow-up. Fourteen patients (15 prostheses) were available for follow-up. The main indication for surgery was rheumatoid arthritis. Mean follow-up was 11 years (8–15). Kaplan-Meier survival analysis showed a survival of 81% at 10 years after surgery. Main reason for revision was particle disease and loosening due to instability and malalignment. Eleven of 14 patients were satisfied, although radiographs showed radiolucencies in 11 patients.
The iBP elbow prosthesis gives a survival rate of 81% 10 years after surgery with a progressive decline beyond 10 years. However, many patients have radiolucencies. Discrepancy between clinical signs and radiological results warrants structural follow-up, to assure quality of bone stock in case revision surgery is indicated.
The study was reviewed and approved by the Medical Ethical Committee of University Medical Center Groningen (METc2016/038).
Level of evidence
Level IV, Case series.
KeywordsiBP Elbow prosthesis Unlinked elbow prosthesis arthroplasty Long-term follow-up
instrumented Bone Preserving
Oxford Elbow Score
Disabilities of Arm, Shoulder and Hand Outcome Measure
Mayo Elbow Performance Score
Total elbow arthroplasty
Visual analogue scales
Joint destruction due to inflammatory arthritis is still the main reason for a total elbow arthroplasty (TEA), although nowadays posttraumatic osteoarthritis is a more common indication for a replacement [1, 2]. As the prevalence of TEA is low compared to knee and hip arthroplasties, reports with long-term follow-up are rather scarce.
The study was reviewed and approved by the Medical Ethical Committee of UMCG (METc2016/038). None of the surgeons was involved in the design of the implant.
In all cases a posterior approach was used with a triceps split technique as described by Pooley [3, 6]. The ulnar nerve was released and protected during the procedure. Release of the collateral ligaments were performed in case of contractures. The radial head was excised in all cases. The humerus and ulna were prepared with preservation of as much bone as possible according to the philosophy of this prosthesis. All humeral components were inserted without cement, except for 6 elbow prostheses in which poor bone quality urged to the use of cement. All ulnar components were cemented.
Post-operatively the elbow was protected by a removable cast for 4 weeks, avoiding active extension. Thereafter, the elbow was mobilized without brace and active triceps training was allowed. Patients were advised to limit weight bearing up to 1 kg repetitively and to 5 kg incidentally.
SPSS statistical software (version 24.0, IBM SPSS, Chicago) was used. Descriptive statistics were used to describe patients’ characteristics, clinical outcomes and scores on the questionnaires. Kaplan-Meier survival analysis was performed with revision as an end point. Kruskal-Wallis Test for independent samples was used to analyze differences in indication for surgery.
Overall, most patients were satisfied with their iBP elbow prosthesis. Only 2 out of 14 patients were not satisfied with the result. One patient was not satisfied, because of ulnar neuropathy and loss of function. Another patient was no longer satisfied because of loosening of the ulnar component that had led to loss of function. No revision arthroplasty was planned though because of severe comorbidities. One patient was indifferent, which left 11 patients (12 elbows) being satisfied with their iBP elbow prosthesis.
Mean MEPS score was 80 points (45–100) indicating a fair-to-good result. Lower scores indicated pain in most cases. Mean DASH score was 44 points (17–70) and mean OES 34 points (14–48). This score usually indicates mild-to-moderate elbow complaints. The underlying disease, rheumatoid arthritis, mainly influenced both scores, as illustrated by the health-related quality of life score: 6 (4–8). Assessment of pain on a 0–10 point scale scored a mean of 2 (0–7), indicating low pain levels.
Mean ROM was 90° (40°-125°), mean flexion 125° (70°-145°), mean extension deficit 35° (5°-70°). Mean pronation 70° (40°-95°), mean supination 75° (40°-95°). Seven out of 15 elbows were unstable. Two of them were grossly unstable and 5 were moderately unstable, although this was not clinically relevant in terms of dislocation. Three of 14 patients had signs of persistent ulnar neuropathy. There were no significant differences in clinical outcomes and survival between indication for surgery.
All together in 15 of 25 cases (revisions and survivals) the radiographs indicated bone loss due to particle disease with PE wear and metallosis as to be expected. The case shown in Fig. 5 demonstrated radiolucencies and pseudotumor, suggestive for metallosis. Painful loosening 10 years after primary surgery led to a revision in which severe bone loss was encountered.
The iBP elbow prosthesis is an unlinked prosthesis. The stability of the joint is provided by the soft tissues, therefore the risk of dislocation is higher than in a linked-type prosthesis [12, 13]. The theoretical advantage of this design is the lower risk of loosening, because of minimal stress on the bone-implant interface .
Our study shows survival rates for the iBP elbow prosthesis of 88 and 81% respectively at 5 and 10 years postoperatively with a progressive decline in survival beyond 10 years. Eleven of 14 patients were satisfied with their elbow as reflected in the scores of the questionnaires. In our study the main reason for revision was loosening with polyethylene wear and metallosis (50%), which is higher compared to the results of Dalemans et al.(33%), but they only had a follow-up of 7.5 years with their series of the iBP elbow prosthesis [5, 12, 13]. In their series with the Kudo 5, an unlinked prosthesis with a mean follow-up of 14.5 years, the main reason for revision was loosening and metallosis as well (61%). The unlinked prostheses were originally developed to render less loosening than linked prostheses, but Voloshin et al. showed in their systematic review no significant difference in clinically relevant loosening between linked and unlinked elbow prostheses .
Over the last years improvements in the quality of PE have been made. A recent study by Popoola et al.  showed that vitamin E blended and crosslinked polyethylene gives lower in vitro wear compared to conventional gamma-irradiated polyethylene in two types of linked, semiconstrained total elbow prostheses. Probably motion in combination with the thin polyethylene in the design of the iBP prosthesis eventually leads to wear, metallosis and loosening.
When revising the iBP we had to revise the ulnar component in 3 of 10 cases.
In 6 of 10 cases persistent instability due to debridement of soft tissue and insufficiency of the collateral ligaments, required revision to a linked-type total elbow prosthesis. In one case a complete iBP revision was performed.
The relatively short survival and the described wear problems and loosening of the ulnar component in combination with the difficulties experienced in revision of an even well-fixed humeral stem have made us decide to stop using this prosthesis.
Another well-known complication after TEA is ulnar neuropathy [15, 16, 17, 18]. In our study 3 patients (20%) had some form of permanent ulnaropathy, despite the ulnar nerve was mobilized and protected during surgery. The reported outcomes on neuropathy after elbow prosthetic joint placement are conflicting. Tanaka et al. did not find ulnaropathy after release of the nerve . On the other hand, not mobilizing the ulnar nerve as shown by Kleinlugtenbelt et al. resulted in 6% ulnaropathy , by Brinkman et al. a high rate of 20% ulnar neuropathy was found . Postoperative ulnar neuropathy rates appear to vary, so we recommend further research to determine whether mobilization of the ulnar nerve is preferred.
Mean arc of motion in our study was 90°, with a mean flexion of 125° and a mean extension deficit of 35°. Mean pronation was 70° and mean supination 75°. Morrey et al.  described that the functional arc of motion required for activities in daily life was 120/30 for flexion/extension and 50/50° for pronation/supination. Five out of 14 patients had a range of motion inferior to this standard. Most of the patients were nonetheless satisfied with their elbow function.
Few studies have been conducted to determine the long-term outcome of the iBP elbow prosthesis. One study by Kleinlugtenbelt et al.  showed a discrepancy between clinical evaluation and radiological signs at short-term follow-up, with a mean follow-up of 4 years. Our study showed this discrepancy too.
Loosening of the ulnar component was seen in 11 patients, although 8 of them did not have any complaints of their elbow. In 9 of these 11 patients radiolucencies around the humeral component were seen. Seven patients had some degree of elbow instability at physical examination without dislocation; 3 of them did show radiological signs of subluxation.
Our current ‘care as usual’ does not routinely include medium or long term follow-up. The outcome of this study has changed our policy and we routinely do a structural follow-up. Patient related outcome measures only will not be sufficient to assess the integrity of these implants. Following this study, another three prostheses have been revised. All three of them with severe polyethylene wear and metallosis.
We were only able to examine a small number of patients. Our study had a retrospective design, which entailed an important loss of patients. The strength of this study is the length of follow-up.
We warrant a structural follow-up for all iBP implants, because of the discrepancy between clinical signs and symptoms and radiological loosening, metallosis and consequent progressive bone loss.
All authors have read and approved the manuscript. DM – patient inclusion, patient follow-up, data analysis, writing article. ALB – study design, patient follow-up, writing article. FB – design of the study, acquisition, revising article. DE – analysis, interpretation data, revising article. SKB – study design, interpretation data, revising article. MS – study design, interpretation data, analysis, writing article.
There is no funding source.
Ethics approval and consent to participate
The study was reviewed and approved by the Medical Ethical Committee of University Medical Center Groningen (METc2016/038). The need for consent was waived by the Medical Ethical Committee of University Medical Center Groningen.
Consent for publication
The authors declare that they have no competing interests.
- 3.Pooley J SR. Elbow arthroplasty. A guide for orthpaedic surgeons using the IBP elbow system. Biomet 2000.Google Scholar
- 10.EuroQol - EQ-5D a standardised instrument for use as a measure of health outcome. 2016 Available at: http://www.euroqol.org/home.html.
- 14.Popoola OO, Kincaid BL, Mimnaugh K, Marqueling M. In vitro wear of ultrahigh-molecular-weight polyethylene and vitamin E blended highly cross-linked polyethylene in linked, semiconstrained total elbow replacement prostheses. J Shoulder Elb Surg. 2017;26(5):846–54. https://doi.org/10.1016/j.jse.2016.12.066.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.